Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Teva Pharmaceutical Industries Yönetim
Yönetim kriter kontrolleri 2/4
Teva Pharmaceutical Industries' CEO'su Richard Francis, Jan2023 tarihinde atandı, in görev süresi 1.75 yıldır. in toplam yıllık tazminatı $ 25.71M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.2% maaş ve 93.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.011% ine doğrudan sahiptir ve bu hisseler $ 2.22M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 7.3 yıldır.
Anahtar bilgiler
Richard Francis
İcra Kurulu Başkanı
US$25.7m
Toplam tazminat
| CEO maaş yüzdesi | 6.2% |
| CEO görev süresi | 1.8yrs |
| CEO sahipliği | 0.01% |
| Yönetim ortalama görev süresi | 2.6yrs |
| Yönetim Kurulu ortalama görev süresi | 7.3yrs |
Son yönetim güncellemeleri
Recent updates
Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Tazminat ve Piyasa: Richard 'nin toplam tazminatı ($USD 25.71M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 13.04M ).
Tazminat ve Kazançlar: Richard şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Richard Francis (56 yo)
1.8yrs
Görev süresi
US$25,706,880
Tazminat
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 1.8yrs | US$25.71m | 0.011% $ 2.2m | |
| Executive VP & CFO | 4.8yrs | US$4.94m | 0.064% $ 12.7m | |
| Executive Vice President of International Markets Commercial | 3.2yrs | US$3.73m | 0.028% $ 5.5m | |
| Executive Vice President of European Commercial | 6.9yrs | US$5.16m | 0% $ 0 | |
| Executive Vice President of Global Operations | less than a year | Veri yok | Veri yok | |
| Senior VP & Chief Accounting Officer | 2.9yrs | Veri yok | 0.00046% $ 91.2k | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Senior Vice President | 2.3yrs | Veri yok | Veri yok | |
| Executive VP & Chief Legal Officer | less than a year | Veri yok | Veri yok | |
| Executive VP & CHRO | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Senior VP & Chief Internal Auditor | 10.4yrs | Veri yok | Veri yok |
2.6yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim: TEVA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 2.2m | |
| Independent Chairman of the Board | 9.8yrs | US$539.99k | 0.036% $ 7.2m | |
| Independent Director | 15.8yrs | US$340.00k | 0.18% $ 36.6m | |
| Independent Director | 9.1yrs | US$355.00k | 0.0094% $ 1.9m | |
| Independent Director | 7.3yrs | US$340.00k | 0.0084% $ 1.7m | |
| Independent Director | 9.1yrs | US$330.00k | 0.0092% $ 1.8m | |
| Independent Director | 4.3yrs | US$325.46k | 0.0056% $ 1.1m | |
| Independent Director | 3yrs | US$330.00k | 0.0043% $ 860.0k | |
| Independent Director | 7.3yrs | US$327.87k | 0.0084% $ 1.7m | |
| Independent Director | 6.3yrs | US$315.25k | 0.0078% $ 1.5m | |
| Independent Director | 1.1yrs | US$176.66k | 0.0011% $ 225.9k |
7.3yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: TEVA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).